SYK · Stryker Corp
Price
Snapshot
50 fields · last close| Market Cap | $112.5B |
| P/E | 29.93 |
| Float | 362.5M |
| Beta | 0.79 |
| Volatility | 19.8% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 73.0 |
| Price | 294.00 |
| Change | −0.22% |
| Prev Close | 294.66 |
| Open | 287.00 |
| Day Low | 286.55 |
| Day High | 293.99 |
| Avg Vol | 2 |
| Avg $ Vol | $678.5M |
| 52W High | 392.55 |
| 52W Low | 267.00 |
| 52W Pos | 21.5% |
| From High | −25.11% |
| From Low | +10.11% |
| Max DD 1Y | −30.54% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +5.93% |
| SMA 50 | −2.26% |
| SMA 200 | −10.08% |
| RSI (14) | 57.6 |
| Vol 30D | 37.0% |
| Vol 90D | 38.5% |
| 1Y Range | 267–393 |
| Daily bars | 535 |
| Perf Week | +5.87% |
| Perf Month | +2.97% |
| Perf Quarter | −8.33% |
| Perf Half Y | −13.34% |
| Perf Year | −20.75% |
| Perf YTD | −15.56% |
| Prev Day | −0.22% |
| Clavix | B |
| Debt / Eq | 0.15 |
| Curr Ratio | 1.89 |
| Int Cover | 6.1× |
| FCF Margin | 17.1% |
| Rev Growth | +11.2% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 35 / 49 |
What SYK does
Stryker Corporation operates as a medical technology company in the United States and internationally.
It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products.
The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications.
The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries.
Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Clavix risk grade
regraded every trading daySYK grades B, 73.0 of 100. Steadiest on Macro Resilience (67), most exposed on Sector Resilience (54, mixed). 0 of the 4 weighted dimensions sit above the Health Care median. Ranks 35 of 49 in Health Care by Clavix score.
How rough the ride is
| SYK | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.79 | 0.84 |
| Volatilityannualized | 19.8% | 21.1% |
| Max drawdown, past yearworst peak-to-trough fall | −30.5% | — |
| Typical daily movemedian absolute daily change | 1.02% | — |
| Days beyond ±3%of the last 252 sessions | 24 (10%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| SYK | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.79 | 0.84 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 53% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| SYK | |
|---|---|
| 1 week | +5.9% |
| 1 month | +3.0% |
| Year to date | −15.6% |
| 1 year | −20.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| SYK | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 16 Sep |
| Average score0 most bearish, 100 most bullish | 52 |
| Bullish · bearisharticles above 60 · below 40 | 16 · 10 |
| Directionarticles whose tone is improving vs worsening | 16 ↑ 10 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| SYK | |
|---|---|
| Revenue growthyear over year | +11.2% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openStryker received FDA 510(k) clearance for Sonopet 3, an updated version of its ultrasonic bone and soft tissue removal device, which the company says delivers enhanced power, precision, and versatility.
Stryker's Q2 2026 sales rose 9.4% to about $6.6 billion, with organic growth near 9%, recovering from a cybersecurity disruption the prior quarter. Adjusted earnings per share climbed roughly 18% to $3.69, and operating margin widened 1.7 percentage points to 27.4%.
Stryker (SYK) announced that current CEO Kevin Lobo will become executive chairman and Spencer Stiles will take over as CEO, effective January 1. The change comes as SYK shares trade around $275, down about 25% over twelve months and 30% below their 52-week high, even though revenue grew 9.4% and earnings grew 44.3% in the most recent quarter. The stock now trades at about 29 times trailing earnings versus 16 times forward earnings, with a PEG ratio of 1.30.
Stryker announced Kevin Lobo will move from CEO to Executive Chair and Spencer Stiles, currently President and Chief Operating Officer, will become CEO on January 1, 2027. Stiles will also join Stryker's Board at that time. The company said the change follows a planned succession process.
Stryker announced a leadership change: CEO Kevin Lobo will become Executive Chair, and Spencer Stiles will take over as CEO on January 1, 2027. Over the past 30 days the share price is down 8.2%, over 90 days it is down 14.9%, and the one-year total shareholder return is down 23.8% (the five-year figure was cut off in the article).
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| MCK | McKesson Corp | B+ | $116.4B | 25.30 | 0.31 | Compare |
| CVS | CVS Health Corp | A- | $118.4B | 23.91 | 0.59 | Compare |
| MDT | Medtronic PLC | A- | $122.1B | 23.15 | 0.59 | Compare |
| HCA | HCA Healthcare Inc | B+ | $101.4B | 14.83 | 1.12 | Compare |
| ELV | Elevance Health Inc | B+ | $92.91B | 18.78 | 0.64 | Compare |
| ISRG | Intuitive Surgical Inc | B- | $151.2B | 47.42 | 1.46 | Compare |
| CI | Cigna Group | A- | $78.96B | 12.15 | 0.26 | Compare |
| ABT | Abbott Laboratories | B+ | $181.1B | 33.41 | 0.55 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.